drugset / Trial / NCT01539915

Pharmacokinetics and Pharmacodynamics of BCT194 in Psoriatic Patients

NCT01539915 ↗

Phase 1 Completed 12 enrolled Novartis Pharmaceuticals
NaSingle-group

Summary

This study will evaluate the pharmacokinetics and pharmacodynamics of BCT194 in psoriatic patients to better understand the skin penetration of topically applied BCT194.

Timeline

Start
2007-04
Primary completion
2007-11
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject BCT194 Unknown 0.5 % Topical

Indications